HotSpots and countermeasures analysis of clinical trial subject recruitment
10.3760/cma.j.cn113565-20230406-00108
- VernacularTitle:药物临床试验受试者招募研究热点与对策分析
- Author:
Bingwei WANG
1
;
Liang MA
;
Ruoyan HAN
;
Jiacheng GUO
;
Ming SONG
;
Ying ZHAO
;
Keke CUI
;
Yan ZHENG
;
Wenjie MA
;
Yanyan LIU
Author Information
1. 郑州大学附属肿瘤医院/河南省肿瘤医院 450008
- Keywords:
Clinical trial;
Subject recruitment;
Bibliometrics;
HotSpot research;
Countermeasure analysis
- From:
Chinese Journal of Medical Science Research Management
2023;36(5):351-355
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study is to understand the hot spots and trends in the recruitment of clinical trial subjects in China over the past 20 years, explore the existing problems and countermeasures, and provide scientific ideas for domestic clinical trial institutions to effectively solve the problem of subject recruitment.Methods:Bibliometric analysis was used to study the relevant literature from three major domestic databases from 2001 to 2021, analyzing key indicators such as annual publication volume, journal distribution, institutional distribution, regional distribution, and high-frequency keyword co-occurrence.Results:A total of 162 articles were selected. The results showed that the overall publication volume in this field showed an upward trend, and the research institutions were diversified, with a concentration of medical and pharmaceutical institutions and universities. The current research hotspots in this field focused on quality and efficiency improvement of subject recruitment, with themes of subject protection, ethical review, regulation development, standardized management, etc.Conclusions:The research in this field has made significant progress, but the overall research level is still relatively weak. Therefore, it is suggested that the country should play a role in macro-regulation, on the one hand, starting with top-level design, promoting the construction of a standardized management system for subject recruitment, continuously strengthening subject protection, and enhancing the effectiveness of scientific recruitment. On the other hand, releasing the potential of grassroots institutions and giving full play to the volume advantage by promoting the sinking of advantageous resources. Meanwhile, great importance should be attached to the development of Phase I clinical trials, giving full play to the strong internal energy of traditional medicine and promoting the development of Chinese traditional medicine. These multi-measures should provide a theoretical basis for exploring the transformation of ′clinical research hospitals′, and promote the high-quality development of new drug research and development in China.
